Ablynx successfully raises €50 million with Secondary Public Offering - Gilde Healthcare

Ablynx successfully raises €50 million with Secondary Public Offering

March 15, 2010

GHENT, Belgium – Ablynx, the biopharmaceutical company focused on the discovery and development of Nanobodies®, announced that it has successfully completed its Secondary Public Offering (the “SPO” or “Offering”) raising €50 million.

The offered shares were priced at €7.5 per share. As a result of the Offering, 6,666,667 new shares, equivalent to €50 million, will be issued by Ablynx. Additionally, 400,000 over-allotment shares, equivalent to €3 million, will be allocated. The over-allotment shares are existing shares and if the over-allotment option is exercised in full, this will result in the sale of the over-allotment shares by the Lending Shareholders.
 
KBC Securities NV and UBS Investment Bank acted as Joint Global Coordinators and Joint Bookrunners, while Piper Jaffray Ltd. acted as Co-Manager to the Offering and while KBC Bank NV and Kempen & Co NV acted as selling agent.
 
For more information, please contact:
 
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling...
July 9, 2025

Gilde Healthcare’s private equity fund combines Artinis and NIRx into a world-leading neuroimaging group

Gilde Healthcare today announces the combined private equity investments in Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States), both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions. This dual transaction brings together two highly...
July 8, 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025